These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 17893768

  • 1. Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity.
    Bernhardt PV, Chin P, Sharpe PC, Richardson DR.
    Dalton Trans; 2007 Aug 14; (30):3232-44. PubMed ID: 17893768
    [Abstract] [Full Text] [Related]

  • 2. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy.
    Bernhardt PV, Chin P, Richardson DR.
    J Biol Inorg Chem; 2001 Oct 14; 6(8):801-9. PubMed ID: 11713687
    [Abstract] [Full Text] [Related]

  • 3. Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues.
    Bernhardt PV, Mattsson J, Richardson DR.
    Inorg Chem; 2006 Jan 23; 45(2):752-60. PubMed ID: 16411711
    [Abstract] [Full Text] [Related]

  • 4. Iron catalysed assembly of an asymmetric mixed-ligand triple helicate.
    Bernhardt PV, Chin P, Richardson DR.
    Dalton Trans; 2004 Oct 21; (20):3342-6. PubMed ID: 15483720
    [Abstract] [Full Text] [Related]

  • 5. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
    Kalinowski DS, Sharpe PC, Bernhardt PV, Richardson DR.
    J Med Chem; 2008 Jan 24; 51(2):331-44. PubMed ID: 18159922
    [Abstract] [Full Text] [Related]

  • 6. PCTH: a novel orally active chelator for the treatment of iron overload disease.
    Lovejoy DB, Kalinowski D, Bernhardt PV, Richardson DR.
    Hemoglobin; 2006 Jan 24; 30(1):93-104. PubMed ID: 16540421
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues.
    Bernhardt PV, Caldwell LM, Chaston TB, Chin P, Richardson DR.
    J Biol Inorg Chem; 2003 Nov 24; 8(8):866-80. PubMed ID: 14564555
    [Abstract] [Full Text] [Related]

  • 8. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
    Kalinowski DS, Richardson DR.
    Chem Res Toxicol; 2007 May 24; 20(5):715-20. PubMed ID: 17402750
    [Abstract] [Full Text] [Related]

  • 9. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB, Lovejoy DB, Watts RN, Richardson DR.
    Clin Cancer Res; 2003 Jan 24; 9(1):402-14. PubMed ID: 12538494
    [Abstract] [Full Text] [Related]

  • 10. Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity.
    Basha MT, Chartres JD, Pantarat N, Ali MA, Mirza AH, Kalinowski DS, Richardson DR, Bernhardt PV.
    Dalton Trans; 2012 Jun 07; 41(21):6536-48. PubMed ID: 22362375
    [Abstract] [Full Text] [Related]

  • 11. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK, Kalinowski DS, Richardson DR.
    Mol Pharmacol; 2008 Jul 07; 74(1):225-35. PubMed ID: 18424550
    [Abstract] [Full Text] [Related]

  • 12. Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands.
    Bernhardt PV, Wilson GJ, Sharpe PC, Kalinowski DS, Richardson DR.
    J Biol Inorg Chem; 2008 Jan 07; 13(1):107-19. PubMed ID: 17899222
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.
    Kalinowski DS, Sharpe PC, Bernhardt PV, Richardson DR.
    J Med Chem; 2007 Nov 29; 50(24):6212-25. PubMed ID: 17963372
    [Abstract] [Full Text] [Related]

  • 14. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
    Liu J, Obando D, Schipanski LG, Groebler LK, Witting PK, Kalinowski DS, Richardson DR, Codd R.
    J Med Chem; 2010 Feb 11; 53(3):1370-82. PubMed ID: 20041672
    [Abstract] [Full Text] [Related]

  • 15. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.
    Bernhardt PV, Sharpe PC, Islam M, Lovejoy DB, Kalinowski DS, Richardson DR.
    J Med Chem; 2009 Jan 22; 52(2):407-15. PubMed ID: 19090766
    [Abstract] [Full Text] [Related]

  • 16. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.
    Becker EM, Lovejoy DB, Greer JM, Watts R, Richardson DR.
    Br J Pharmacol; 2003 Mar 22; 138(5):819-30. PubMed ID: 12642383
    [Abstract] [Full Text] [Related]

  • 17. Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity.
    Bernhardt PV, Chin P, Sharpe PC, Wang JY, Richardson DR.
    J Biol Inorg Chem; 2005 Nov 22; 10(7):761-77. PubMed ID: 16193304
    [Abstract] [Full Text] [Related]

  • 18. Observation of redox-induced electron transfer and spin crossover for dinuclear cobalt and iron complexes with the 2,5-di-tert-butyl-3,6-dihydroxy-1,4-benzoquinonate bridging ligand.
    Min KS, Dipasquale AG, Rheingold AL, White HS, Miller JS.
    J Am Chem Soc; 2009 May 06; 131(17):6229-36. PubMed ID: 19358538
    [Abstract] [Full Text] [Related]

  • 19. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
    Chaston TB, Richardson DR.
    Am J Hematol; 2003 Jul 06; 73(3):200-10. PubMed ID: 12827659
    [Abstract] [Full Text] [Related]

  • 20. Iron chelation equilibria, redox, and siderophore activity of a saccharide platform ferrichrome analogue.
    Dhungana S, Harrington JM, Gebhardt P, Möllmann U, Crumbliss AL.
    Inorg Chem; 2007 Oct 01; 46(20):8362-71. PubMed ID: 17824601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.